Inborn oxidative phosphorylation defect as risk factor for propofol infusion syndrome

• Verfasst von: Vanlander, Arnaud Vincent [VerfasserIn]
• Verfasst von: Okun, Jürgen G. [VerfasserIn]
• Titel: Inborn oxidative phosphorylation defect as risk factor for propofol infusion syndrome
• Verf.angabe: A.V. Vanlander, P.G. Jorens, J. Smet, B. De Paepe, W. Verbrugghe, G.G. Van Den Eynden, F. Meire, P. Pauwels, N. Van Der Aa, S. Seneca, W. Lissens, J.G. Okun and R. Van Coster
• Umfang: 6 S.
• Fussnoten: Gesehen am 22.10.2018
• Titel Quelle: Enthalten in: Acta anaesthesiologica Scandinavica
• Jahr Quelle: 2012
• Band/Heft Quelle: 56(2012), 4, S. 520-525
• ISSN Quelle: 1399-6576
• DOI: doi:10.1111/j.1399-6576.2011.02628.x
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1582148538

Abstract

Propofol is an anesthetic agent widely used for induction and maintenance of anesthesia, and sedation in children. Although generally considered as reliable and safe, administration of propofol can occasionally induce a potentially fatal complication known as propofol infusion syndrome (PRIS). Mitochondrial dysfunction has been implicated in the pathogenesis of PRIS. We report on an adult patient with Leber hereditary optic neuropathy (LHON) who developed PRIS. He was a carrier of the m.3460G>A mutation, one of the major three pathogenic point mutations associated with LHON. The propositus was blind and underwent propofol sedation after severe head injury. Five days after start of propofol infusion, the patient died. The activity of complex I of the oxidative phosphorylation (OXPHOS) system was severely deficient in skeletal muscle. Our observation indicates that fulminate PRIS can occur in an adult patient with an inborn OXPHOS defect and corroborates the hypothesis that PRIS is caused by inhibition of the OXPHOS system.